Anakinra
Orphan Drug Cold Chain RequiredFDA Approved
Description
Anakinra is an interleukin-1 receptor antagonist (IL-1Ra) used to treat several inflammatory conditions. It works by blocking the effects of IL-1, a protein that causes inflammation.
Indications & Therapeutic Use
Cryopyrin-Associated Periodic Syndromes (CAPS)
Global Availability (5 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Anakinra
| Generic Name | Anakinra |
| Brands | 1 brand available |
| Active Ingredient | Anakinra |
| Drug Class | Cryopyrin-Associated Periodic Syndromes (CAPS) |
| Manufacturer | Swedish Orphan Biovitrum AB |
| Dosage Forms | Subcutaneous injection |
| Medical Code | L04AC04 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Required |
| Lead Time | 14 days |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT00397340 |
| Countries | 5 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations6 Validated Nodes